FULCRUM THERAPEUTICS, INC. Noncash or Part Noncash Acquisition, Intangible Assets Acquired
FULCRUM THERAPEUTICS, INC. (FULC) reported Noncash or Part Noncash Acquisition, Intangible Assets Acquired of $25.50 million for the 12-month period ending 2019-12-31, per its 10-K/A filed 2023-06-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 · last filed 2023-06-23
- FULCRUM THERAPEUTICS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2019-12-31 was $0.00.
- FULCRUM THERAPEUTICS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2019-09-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2019-06-30 was $0.00.
- FULCRUM THERAPEUTICS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2019-03-31 was $25.50M.
- FULCRUM THERAPEUTICS, INC. noncash or part noncash acquisition, intangible assets acquired for fiscal 2019 was $25.50M.
| Period end | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | $0.00 derived: sum of 2 quarters · filed 2023-06-23 | $0.00 derived: sum of 3 quarters · filed 2023-06-23 | $25.50M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $25.50M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $25.50M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $25.50M 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |